OneOme

Read our full release with quotes from Karen Merritt, Co-Founder of Advocates for Universal DPD/DPYD Testing and James Kelley, MD, PhD, Chief Medical Officer at OneOme. This update is the result of years of patient safety advocacy work across the industry. Thank you to everyone who helped make this happen. https://lnkd.in/e_ggePGt #pharmacogenomics, #pgx, #patientsafety, #oncology,

OneOme PGx Office Hours - Our next time slots are this Thursday at 12 pm Eastern AND 12 pm Central. Pick the time that works for you! We'll discuss a case study, how to read the OneOme report, and payment options for PGx. Sign up here and bring your questions: https://wkf.ms/4ngc3Y7

Big thanks to our partners at Ochsner Health for joining us in leading a powerful panel discussion at PGRN-ClinPGx 2025! "PGx Into Practice: The Ochsner Health Oncology Program for Safer Chemotherapy" was a dynamic look into how pharmacogenomics (PGx) can be successfully implemented in oncology (and beyond) to reduce the risk of adverse drug events and improve patient safety. We’re incredibly proud to have collaborated with Catherine Oliver, PharmD, BCPS, DPLA, CPGx; Serena Mitaly, PharmD; and Gillian Bell, PharmD; with expert moderation by our own Ghada Elnashar, PharmD, MS, to highlight the real-world challenges and wins of PGx implementation. To everyone who attended, asked thoughtful questions, and shared your enthusiasm for advancing precision medicine: thank you. Your passion and persistence is what drives PGx and patient safety forward. Pharmacogenomics Global Research Network (PGRN) ClinPGx Clinical Pharmacogenetics Implementation Consortium PharmGKB

Are you heading to the PGRN 2025 Scientific Meeting in Collaboration with ClinPGx? The OneOme team will be there and we'd love to connect. Send us a note or stop by the booth. See you next week! #PGRNClinPGx25 Ghada Elnashar, PharmD, MS, Jason Walker, Brett Miller, Doug Prangley, Travis Thompson, Clinical Pharmacogenetics Implementation Consortium, Pharmacogenomics Global Research Network (PGRN), ClinPGx

New ACS CAN Study Underscores the Urgent Need for Greater Awareness of Pharmacogenomic Testing in Cancer Care A recent Journal of the American Medical Association (JAMA) Network Open study from American Cancer Society Cancer Action Network found that fewer than half of cancer patients are aware of pharmacogenomic (PGx) testing. Once informed, 70% were concerned about starting treatment without it. Many commonly prescribed chemotherapy and supportive care medications have known gene-drug interactions that can influence efficacy and increase risk of adverse events. If you’re already using PGx in your practice—thank you. Keep sharing its value with peers and patients. If not, OneOme can help integrate PGx into your workflow. Let’s help reduce reduce the risk of adverse events for your patients. https://lnkd.in/gNcATabZ

We have a few spots left if you'd like to join! If these times don't work, feel free to DM us your questions and we'll reach out with answers. Thanks to everyone's who's signed up. Ghada Elnashar, PharmD, MS, Brett Miller and Travis Thompson will talk to you on Thursday!

Join us for OneOme PGx Office Hours—an education and interactive discussion for all clinicians new to OneOme's pharmacogenomics (PGx) testing or curious about getting started.   🗓 Date: Thursday, July 24 🕛 Available Times (your choice!): 12:00-12:30 PM Eastern, Central or Pacific Bring your questions – Let's advance precision prescribing together!   🔗 Register here: https://wkf.ms/44B9rfH

🎉 A huge THANK YOU to everyone who submitted comments to the FDA Request for Public Comment on Dihydropyrimidine Dehydrogenase (DPD) Deficiency and the use of fluoropyrimidine chemotherapy drugs (fluorouracil and capecitabine)! Your insightful, detailed, and passionate comments underscore the critical importance of pharmacogenomics in enhancing patient safety and care. Special shout-out to Karen Merritt, Ken Surprenant, Advocates for Universal DPD/DPYD Testing, Pharmacogenomics Global Research Network (PGRN), Sony Tuteja, St. Elizabeth Healthcare; Nihal El Rouby, Josiah Allen, Douglas Flora, Brooke Holbrook, Mollie Beck, Howard McLeod, Essentia Health, Fight Colorectal Cancer, and College of American Pathologists (CAP) and so many others for your impactful advocacy! We at OneOme are thrilled to be a part of the powerful advocacy and thoughtful dialogue around personalized medicine. Each comment helps drive awareness and action towards safer treatment for cancer patients. Together, let's continue advocating for safer, personalized cancer treatments. Explore the impactful comments here and see firsthand the collective dedication to patient safety and personalized medicine: https://lnkd.in/ee36bhSg

The latest news on DPD Deficiency. An undetected deficiency and an avoidable death at a top tier US cancer center. With each new discovery of these adverse events, the profession needs to learn how to improve its treatment delivery. It is past time for guidelines to move from “consider” to recommending or requiring testing. #test4DPD #5FU #capecitabine #NCCN #FDA #AACR https://lnkd.in/eidC7an8

The OneOme team applauds the latest update from National Comprehensive Cancer Network® (NCCN®), strengthening guidelines around DPYD testing prior to fluoropyrimidine therapy for patients with #ColonCancer: “Testing for DPYD genetic variants should be considered prior to fluoropyrimidine therapy. After discussions regarding risk assessment, patients may choose DPYD genetic testing.” (NCCN Clinical Practice Guidelines in Oncology, Colon Cancer, Version 2.2025 — March 31, 2025) If your organization is already offering #pharmacogenomic testing—thank you! Your commitment is helping reduce #chemotoxicity risk and improve patient care. Not yet offering DPYD testing? OneOme can get you started today. We offer: ·     Single-gene #DPYD or comprehensive panel covering supportive care ·     4-day turnaround time for samples at our lab – overnight shipping available ·     Ordering, results delivery and online decision support through our portal or EHR integration Take action now to align with NCCN’s 2025 Guidelines—and help provide safer, personalized care for your patients.